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Prevention of hemodialysis subclavian vein catheter infections by
topical povidone-iodine. Subclavian catheter (SCC) related infections
are a major cause of morbidity in hemodialysis patients, the vast
majority due to staphylococci species. Povidone-iodine (Pt) has proven
anti-staphylococcal activity. Therefore, a randomized controlled trial of
topical P1 ointment was undertaken to evaluate the impact of this
prophylactic intervention on the incidence of SCC related infections in
hemodialysis patients. The role of S. aureus nasal carrier state in the
acquisition of infection was also evaluated. Patients requiring SCC for
temporary hemodialysis access were randomized to receive the treat-
ment (T; N = 63) or sterile gauze dressings alone (C; N = 66). Catheter
duration ranged from 2 to 210 days in both groups, with a mean of 38.6
days in T and 36.2 days in C (NS). Exit site (ES) infections were
significantly less in T (5%) versus C (18%) (P < 0.02); tip colonization
(TC) was 17% in T versus 36% in C (P < 0.01), while the incidence of
septicemia (S) was also significantly less in T (2%) versus C (17%; P <
0.01). S. aureus nasal carriers were at a threefold higher risk of SCC
related septicemia (0.009/day) than noncarriers (0.003/day; P < 0.05).
The beneficial effect of P1 ointment was most evident in this high risk
group of S. aureus carriers: ES = 0% T versus 24% C, TC = 12% T
versus 42% C, S = 0% T versus 29% C, P < 0.05. There were no
adverse effects of the treatment. The routine application of topical P1
ointment to temporary hemodialysis catheter exit sites is effective in
reducing SCC related infections.
Both chronic access problems and the development of acute
renal failure create a need for immediately usable, easily
inserted vascular access which is suitable for repetitive hemo-
dialysis and compatible with outpatient activities. Percutane-
ously inserted subclavian catheters (SCC) provide the nephrol-
ogist with an excellent temporary access for hemodialysis.
However, these accesses are subject to several serious compli-
cations, one of which is sepsis, and the reported incidence of
subclavian catheter related septicemia varies from 9% to 25%
[1-8].
As the majority of SCC infections have been shown to be due
to either Staphylococcus epidermidis or Staphylococcus aureus
[6, 7], this represents an ideal setting for effective prophylaxis.
However, studies to date have failed to prospectively evaluate
in a large number of patients, the efficacy of prophylactic
strategies to decrease the incidence of infection in SCC used for
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chronic hemodialysis. The current study was undertaken to
determine, in a prospective trial, the effectiveness of the use of
topical povidone-iodine ointment in reducing the incidence of
SCC related infection. We also examined the contribution to the
incidence of infection of S. aureus nasal carriage in the dialysis
population.
Methods
Patients with either acute or chronic renal failure requiring
subclavian catheters for hemodialysis access were randomly
assigned to receive either the treatment ointment applied to the
exit site (T) or sterile gauze alone (C). The randomization
process was blinded and accomplished prior to the line insertion
by selecting the designation from a box which originally con-
tained an equal number of treatment and nontreatment assign-
ments. Once chosen, the designation was discarded. Patients
with acute or chronic renal failure were randomized separately.
Informed consent was obtained. Nasal cultures were taken at
the time of insertion of the catheter and at weekly intervals for
three weeks while the SCC remained in place, to determine S.
aureus nasal carrier status. Culturette-2 rayon tipped swabs
(Marion Scientific Division, Kansas City, Missouri, USA) were
used to swab the anterior flares, and were streaked onto blood
agar plates. The presence of S. aureus organisms was deter-
mined by the routine microbiology laboratory using tube coag-
ulation tests, and DNAase by the plate method. One hundred
and twenty-nine patient entries with a total of 171 subclavian
catheters were prospectively evaluated for catheter related
infections. While the patients with acute renal failure were in
patients, the majority of the patients with chronic renal failure
had their catheters inserted as out patients. Catheters were
never inserted into actively infected patients; intermittent fern-
oral lines were used for dialysis access until the sepsis was
eradicated. If a patient with a previous SCC required a second
insertion, they were considered as a new patient entry, and
were re-randomized and a new site used, after the previous
sepsis had been adequately treated with appropriate antibiotics.
All SCC were inserted by staff nephrologists or senior
nephrology trainees. Physicians wore masks, sterile gowns and
gloves. Both the patient and the assisting nurse wore masks.
Following a strict protocol, skin preparation with povidone-
iodine surgical scrub, removed with sterile water and followed
by povidone-iodine solution was uniform in all patients. Head,
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neck and anterior chest were draped with sterile towels.
Lidocaine (2%) was given as local anesthetic.
Single lumen polyurethane hemodialysis catheters varying
from 12 to 19 cm in length (Argon, Squibb Co, Athens, Texas,
USA), were inserted in a standard manner without subcutane-
ous tunnelling. The catheter was fixed to the skin with a 3-0 silk
suture. Those patients randomized to receive the treatment had
1 g of 10% sterile povidone-iodine ointment (Betadine, Purdue
Frederick mc, Toronto, Canada) applied to the gauze adjacent
to the skin entry site. All sites were dressed with sterile gauze
adjacent to the catheter hub and secured with porous tape.
Post-insertion, and after each dialysis, the catheters were filled
with 7 to 10,000 units of heparin depending on catheter length.
All dressings were changed at the time of each dialysis treat-
ment by trained hemodialysis nurses. All patients had the skin,
including the exit site and catheter hub, prepped with povidone-
iodine solution, and the treatment group received the ointment
reapplication at each dressing change. The subclavian catheters
were used only for dialysis, and were removed when no longer
required for this function. Therefore the duration of the catheter
in days reflects the number of uses for dialysis (3 treatments per
week).
Exit site (ES) swabs were taken if the area appeared erythe-
matous or exudative and when the line was removed. If ES
grew more than 15 colonies of one organism and/or gram stain
revealed many white blood cells, the line was removed. All
available catheters were removed under sterile conditions,
including a skin prep of the exit site which removed any
remaining povidone-iodine ointment, and the tips were severed
using sterile scissors. All tips were cultured using the Maki
technique [10]. Two peripheral blood cultures were drawn from
patients with temperatures over 38.5°C (aerobic and anaerobic
Bactec culture bottles). If the febrile patient appeared ill or was
hemodynamically unstable, the SCC was removed prior to
knowledge of blood culture results. Otherwise SCC were left
until the results of the blood cultures were known. If the blood
cultures were positive in the presence of no other identifiable
focus of infection, the SCC was removed. Bacterial isolates
were identified by routine bacteriological techniques. S. aureus
was identified using tube coagulation tests. Phage typing was
not performed.
Definition of outcomes
Exit site and tip cultures were defined as positive if at least 15
colonies of one organism were grown. Line related sepsis was
defined as present if peripheral blood cultures were positive
with no other focus of infection demonstrable. For coagulase
negative staphylococci, growth in two or more blood culture
bottles was required to indicate significant bacteremia.
Insertion difficulty was graded by the physician according to
a 3 point scale. The number 1 represented the easiest insertion,
requiring a single skin puncture and less than 10 minutes. Two
was two to three punctures taking 10 to 30 minutes and 3 was
more than three punctures taking more than 30 minutes.
For technical problems (clotting, bleeding, malfunction),
catheters were changed over a guide wire (preserving the site) if
there was no evidence of infection. For this reason some
patients had more than one catheter per site, but these were
considered a single patient entry.
Statistical analysis
Chi square and Fischer exact tests were performed to evalu-
ate the difference between the groups with respect to infection
rates. Student's t-tests were performed in analyzing continuous
variables such as age and duration of catheter site. Means are
reported as plus or minus standard error. Life table analysis
was performed to assess the differences between groups with
respect to the duration of catheter in relation to septic events,
using the Mantel Cox procedure (Biomedical Data Processing,
life table and survival function, BMDP Statistical software mc,
Los Angeles, California, USA, 1987). Statistical significance
was considered at a P value <0.05. All tests were two-tailed.
Ninety-five percent confidence intervals (CI) for the difference
in event rates were calculated in the usual manner [11]. Relative
risk reduction (RRR) was calculated using the formula
Pc — Pt
RRR =
Pc
where Pc and Pt represent the percentage of positive outcomes
in the control and treated groups, respectively [12]. Other than
the life table analysis, all computatations were executed using
Microstat Software (Ecosoft Inc. Indianapolis, Indiana, USA,
1984).
Results
Of the 129 patients randomized, 63 received povidone-iodine
(T) and 66 sterile dressings alone (C). A total of 171 catheters
were inserted. Thirty-two patients had more than one catheter
per site. Forty-seven percent (15 of 32) of these were in the
treatment group, 53% (17 of 32) were in the control group (NS).
The greatest number of catheters placed in a single site was six,
this was in the povidone-iodine group. Seventy-five percent of
patients (97 of 129) had only one catheter. Only one hundred
and forty-eight tips were available for culture (T = 75, C = 73)
due to loss of catheter at home, failure of tips to reach the
microbiology laboratory, and transfer of the patient to another
institution. One patient was excluded from the study as he was
inadvertently changed from the C to the T group.
Equality between groups
The two groups were similar with respect to age, the numbers
of acute versus chronic renal failure patients and underlying
diseases (Table 1). Variables specifically relating to subclavian
catheters, such as number per site, difficulty of insertion, and
duration were also equally distributed between the two groups.
Analysis comparing acute and chronic renal failure patients
within the T and C groups revealed no difference, therefore the
original stratification within groups was collapsed.
The overall S. aureus nasal carrier (SAN+) rate was 26%. Of
the 31 patients with acute renal failure, 9 (29%) were SAN +
whereas 16 of 98 (16%) of those with chronic renal failure were
SAN+. The SAN+ rate was 14 of 63 (22%) in the treatment
group and 21 of 66 (32%) in the control group (P = 0.22). The
mean number of catheter days at risk in SAN + patients was
significantly longer in the treatment group (40.3 6.1 days) as
compared to the control group (30.6 7.7 days; P < 0.01).
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Table 1. Demographic and clinical variables equality between groups
Treatment Control
Patient entries 63 66
Age (years) 49.8 2.1 53.0 1.9
Acute:chronic 19:44 12:54
Malignancy 2 2
Immunosuppressed 4 2
Diabetes mellitus 5 6
S. aureus carriers 14 21
Total no. of catheters 84 87
Catheter days at risk
Total 2437 2397
Mean 38.6 5.1 36.2 4.6
Range 2—2 10 2—2 14
Catheters per site 1.38 0.12 1.31 0.07
Insertion difficulty 1.26 0.06 1.12 0.03
There was no statistically significant difference.
Table 2. Incidence of subclavian catheter related positive cultures
overall
Treatment Control P
Relative
risk
reduction
95%
Confidence
interval
Exit site 3/63 (5%) 12/66 (18%) <0.02 72% 4—22%
Catheter tips 13/75 (17%) 27/73 (37%) <0.01 52% 7—33%
Blood 1/63 (2%) 11/66 (17%) <0.01 93% 6—24%
The rate of septicemial 100 patient days at risk was T = 0.04and C =
0.46 (P < 0.01). There were 3 nonline related episodes of septicemia (2
in T and 1 in C group) not included in this Table, see text for details.
Effect of topical povidone-iodine on incidence of infection
Exit sites. There were three infected exit sites (ES) in the
treated group (5%) and 12 (18%) in the controls (P < 0.02, CI
4 to 22%; Table 2). The relative risk reduction in ES infection
attributable to the treatment was 72%.
Catheter tips. Of the 75 catheter tips available for culture in
the treated group, 13 were colonized (17%), whereas the
colonization rate in the control group was 37% (P <0.01, CI
7 to 33%). The relative risk reduction for tip colonization due to
povidone-iodine was 52%. If the incidence of colonization was
calculated on the basis of the number of sites which developed
a colonized catheter (that is, where N is equal to the number of
patient entries), the difference between the rate of colonization
in the treated group (17%, 11 of 63) versus the control group
(38%, 25 of 66) is still significantly different (P =0.012, CI 6
to 37%, RRR = 54%).
Blood cultures. The overall rate of septicemia in the popula-
tion was 11 6% with 5% of events occurring in the treated group
and 18% in the controls (P < 0.02, CI = 4 to 22%). The relative
risk reduction attributable to treatment is 78%. However, there
were three cases of non-SCC related septicemia in the study:
two cases in the treated group (Enterococcus fecalis from a
wound infection and Streptococcus pneumoniae from a pulmo-
nary source) and one case in the control group (Enterococcus
fecalis from the urinary tract). Of interest is that neither patient
with E. faecalis bacteremia had either positive tip or exit site
cultures despite positive blood cultures. All had their lines
removed prior to receiving antibiotics. Therefore, if one looks
only at SCC related septicemia, the rate is 2% (1 of 63) in the
treated group and 17% (11 of 66) in the controls (P < 0.01. CI
Table 3. Incidence of subclavian catheter related positive cultures in
S. aureus nasal carriers
Infections Treatment Control P
Relative
risk
reduction
95%
Confidence
interval
Exit site 0/14 (0%) 5/21 (24%) <0.05 100% 6—32%
Blood 0/14 (0%) 6/21 (29%) <0.05 100% 10—48%
Catheter 2/17 (12%) 11/26 (42%) <0.05 71% 6—54%
tips
Mean days 40.3 6.1 30.6 7.7 <0.01
at risk
6 to 24%). This represents a 93% relative risk reduction of
septicemia, attributable to the use of povidone-iodine ointment.
Thirty-three percent (4 of 12) of all line related septic epi-
sodes were due to S. epidermidis; three of the four occurred in
the control grOup. The remaining line related septic episodes
were due to S. aureus (8 of 12). Of the 12 SCC related
septicemias, (92%) were in the control group.
All patients with suspected sepsis had their catheter removed
and received 1 g of Vancomycin intravenously.
Staphylococcal aureus infection
As S. aureus nasal carriage is believed to be an important
predisposing factor for S. aureus septicemia, the effect of the
topical ointment was analyzed separately in this high risk
group. No S. aureus nasal carrier (SAN+) in the treated group
had either exit site (ES) infection or septicemia (Table 3). Two
catheter tips in this group were colonized, both with S. epider-
midis. In the control group, there were seven episodes of
septicemia, one of which was not line related (E. fecalis). All (6
of 6) of these line related septic episodes were due to S. aureus
in the SAN+ control group. Three of the five ES infections and
7 of 11 tip colonizations were similarly due to S. aureus. The
differences between treated and control groups are both statis-
tically and clinically significant, with povidone-iodine resulting
in 100% relative risk reduction for S. aureus infections in this
high risk group.
There were 12 episodes of line related septicemia in the entire
study population, eight (66%) of which were due to S. aureus
and all of these occurred in the control group. Six of these eight
S. aureus septic episodes (75%) occurred in the small group (N
21) of SAN + who did not receive povidone-iodine treatment.
If one calculates the relative risk per day of developing septi-
cemia with any organism in the control group, it was three times
greater in the S. aureus carriers (6 of 21, 644 days at risk) than
in the non S. aureus carriers (5 of 45, 1753 days at risk; P <
0.05).
There was one death in the control group directly attributable
to S. aureus septicemia, attesting to the potential seriousness of
this complication.
Relation between duration of catheters and infection
The total catheter days at risk in both groups was not
significantly different (T = 2437, mean 38.6 5.1 days, vs. C =
2397 mean 36 4.6 days) and the range was similar in both
groups. (2 to 210 in T and 2 to 214 in C).
The life table analysis (Fig. 1) demonstrates a sinnificant
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Fig. 1. The vertical axis represents the cumulative proportion of cath-
eters not removed for septic complications and the horizontal axis
represents the catheter duration in days. The numbers along the two
lines are the absolute number of catheters remaining (T = treatment, C
= control). There is a significant difference between the two groups and
there is a trend towards early infections in the control group, see text
for details. P < 0.003.
difference between the treatment and control groups (Mantel-
Cox P = 0.003), with respect to the proportion of catheters
surviving without sepsis. The analysis also suggests that the
majority of septic events in the control group occurred in the
early period of catheter use (< 21 days). This tendency to early
infection cannot be proven statistically due to the smaller
number of patients with catheters of prolonged duration.
Sixty percent (78 of 129) of patients had the same catheter site
for a period exceeding 21 days (54% in the treatment group,
46% in the control group, NS).
Except for sepsis, lines were removed for similar reasons in
each group (resolution of acute renal failure, change to perito-
neal dialysis, mechanical difficulties, maturation of chronic
access and patient death). The percentage of suspected sepsis
which was confirmed was also similar in both groups (T = 50%,
C = 66%).
Morbidity and mortality
There was one episode of hydropneumothorax after subcla-
vian line insertion in the treated group. There were no technical
complications in the control group. There was no adverse effect
observed subsequent to the use of povidone-iodine ointment.
There were four deaths in the treated group, two in the acute
renal failure group: one due to progressive cardiac dysfunction
and one due to respiratory failure. There were two deaths in the
chronic renal failure treated group, one of which was related to
perforated bowel and the attendant postoperative complica-
tions, and the second due to metastatic cancer.
Of the five deaths in the control group, one was in the acute
renal failure group, due to heart failure. Three of the four deaths
in the chronic renal failure population were attributed to myo-
cardial infarctions. The fourth was a direct result of S. aureus
septicemia despite appropriate therapy.
Discussion
In view of the prevalence of infectious complications of
subclavian line access for hemodialysis, we sought a prophy-
lactic programme to reduce the incidence of this important
complication. We began by standardizing the technique; imple-
menting a surgical skin preparation and dry gauze dressing. We
chose povidone-iodine as the appropriate prophylactic agent to
study in view of its excellent anti-staphylococcal action and its
topical application [131. We discarded the concept of a double-
blind placebo trial, reasoning that a placebo ointment may in
fact promote infection by providing a culture medium, necessi-
C tating a third untreated group and decreasing the feasibility of
the study. The study was therefore designed as a randomized,
controlled trial without placebo.
The results indicate the effectiveness of the treatment in
reducing the incidence of line related infections. The overall
incidence of septicemia in our study population was 11.6%,
while that of line related septicemia was 9.6%. These results are
in keeping with those of Dahlberg, Yutuc and Newcomer [4]
and Kozeny et al [5], who used sterile insertion and catheter
care techniques similar to the current study. Studies reporting
higher rates of infectious complications (15 to 25%) used
different insertion protocols and the lines were multipurpose,
serving as access for bloodletting, as well as various infusions,
including TPN [6—8, 14—16]. Therefore it is possible that the
insertion protocol, and care of catheters probably also have an
important role in the minimization of catheter related infection.
The basis for the nasal carrier state and the nature of the
relation to subsequent infection (that is, causal or a marker of
impaired local defense mechanisms) is controversial and has
recently been reviewed [18]. S. aureus nasal carriers have been
identified as a high risk group for S. aureus infection [18, 191
and our data confirm this predisposition.
In our nontreated patients the risk of septicemia per day of
catheter use is increased threefold in those patients who are S.
aureus carriers as compared with the non-carriers (0.009 vs.
0.003 per day). No patient who was a S. aureus carrier and
received povidone-iodine topical therapy, had septicemia in 564
catheter days at risk. In view of the seriousness of S. aureus
sepsis, this effect is of major clinical importance.
The incidence of tip colonization was significantly reduced
(by 21%) with the use of povidone-iodine. The relationship
between tip colonization and infectious episodes (exit site or
blood stream) was examined. There was no episode of line
related septicenlia and there were only two exit site infections
which were not associated with tip colonization. These findings
suggest a correlation between tip colonization and more serious
infection. The causal nature of this relationship, however, has
not been addressed in this study.
It has been suggested that the longer the duration of the
catheter, the greater the risk of infection [14, 15, 20], and it is
common clinical practice to change central lines routinely alter
four to seven days of use. The current results contest this
dogma, as we found substantial sepsis free catheter survival in
both groups (80 to 90% at 60 days; Fig. 1). As there can be
significant morbidity [1—3] associated with the insertion of
subclavian lines, this finding has important clinical relevance.
In this study, 60% of catheter sites lasted longer than 21 days.
Of the five episodes of septicemia in this group of long lasting
catheters four (80%) occurred in the non treatment group; one
occurred in the povidone-iodine group.
Other strategies for reducing infection rates have been em-
ployed. Yu et al [19] demonstrated the usefulness of a five day
course of Rifampin with topical bacitracin ointment to the nares
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in reducing S. aureus nasal carriage and subsequent septic
episodes. Problems with this strategy include the emergence of
resistant strains of S. aureus, possible hepatotoxicity from
long-term use of the drugs, cost, and the finding that a signifi-
cant proportion of patients had recurrence of the nasal carrier
state with cessation of therapy. Topically applied mupirocin
nasal ointment has been recently shown to reduce the S. aureus
nasal carriage rate in hemodialysis patients [22]. One would
expect this therapy also to be effective in reducing the incidence
of subclavian catheter infections due to S. aureus, however,
this remains to be established. Maki et a! [211 have advocated
the use of a silver impregnated cuff inserted subcutaneously at
the catheter hub to reduce infection. This approach has not yet
been studied in hemodialysis catheters.
The classical pathogenesis for line related sepsis is that the
organisms migrate from the skin along the outside of the
catheter and gain access to the tissues and the blood stream via
the outside wall of the catheter. A more recent hypothesis is
that the contamination occurs via entry to the lumen of the
catheter at the junction of the hub and the connecting line (hub
hypothesis) [23]. Our study does not support the hub hypothesis
as the povidone-iodine ointment was applied to the skin entry
site and would be expected to have no impact on organisms
gaining entry to the patient via the line lumen.
The principal basis for the effectiveness of the povidone-
iodine ointment is that it provides a barrier to the migration of
skin organisms into the puncture site producing infection. Some
hemodialysis catheters have specific design features which
might provide an additional barrier to infection (long subcuta-
neous tunnel or dacron cuff) and whether topical povidone-
iodine ointment provides the same degree of benefit with these
devices will require further study.
In view of the simplicity, low cost and lack of any systemic
effects, povidone-iodine would appear to be one of the prophy-
lactic treatments of choice for hemodialysis catheters.
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